Company Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 31, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 296 |
| CEO | Todd Watanabe |
Contact Details
Address: 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 United States | |
| Phone | 805 418 5006 |
| Website | arcutis.com |
Stock Details
| Ticker Symbol | ARQT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001787306 |
| CUSIP Number | 03969K108 |
| ISIN Number | US03969K1088 |
| Employer ID | 81-2974255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd Franklin Watanabe M.A. | President, Chief Executive Officer and Director |
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder and Independent Director |
| Dr. Patrick E. Burnett M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| L. Todd Edwards | Senior Vice President and Chief Commercial Officer |
| David J. Topper | Senior Vice President and Chief Financial Officer |
| Rajvir Madan | Chief Digital and Technology Officer |
| Latha Vairavan | Vice President of Finance and Investor Relations |
| Courtney Barton | Vice President and Chief Compliance Officer and Privacy Officer |
| Masaru Matsuda Esq., J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Amanda Sheldon | Head of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 144 | Filing |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |